IP Library › Patent Application 11482832
Patent Application
App. No. 11/482,832

HLA class I A2 tumor associated antigen peptides and vaccine compositions

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/482,832
Abstract

A composition or vaccine composition comprising at least one peptide that has less than 600 contiguous amino acids having 100% identity to a native sequence of CEA, HER2/neu, MAGE2, MAGE3, or p53, the peptide further comprising at least one epitope selected from Table 6.

Claims (193)

1 . A composition comprising at least one peptide, the peptide comprising an isolated, prepared epitope consisting of a sequence selected from the group consisting of:

VLYGPDAPTV,

(SEQ ID NO:1)

YLSGANLNV,

(SEQ ID NO:2)

ATVGIMIGV,

(SEQ ID NO:3)

LLPENNVLSPV,

(SEQ ID NO:4)

KLCPVQLWV,

(SEQ ID NO:5)

KLBPVQLWV,

(SEQ ID NO:6)

SLPPPGTRV,

(SEQ ID NO:7)

SMPPPGTRV,

(SEQ ID NO:8)

KLFGSLAFV,

(SEQ ID NO:9)

KVFGSLAFV,

(SEQ ID NO:10)

VMAGVGSPYV,

(SEQ ID NO:11)

ALCRWGLLL,

(SEQ ID NO:12)

FLWGPRALV,

(SEQ ID NO:13)

HLYQGCQVV,

(SEQ ID NO:14)

ILHNGAYSL,

(SEQ ID NO:15)

IMIGVLVGV,

(SEQ ID NO:16)

KIFGSLAFL,

(SEQ ID NO:17)

KVAELVHFL,

(SEQ ID NO:18)

LLTFWNPPV,

(SEQ ID NO:19)

LVFGIELMEV,

(SEQ ID NO:20)

QLVFGIELMEV,

(SEQ ID NO:21)

RLLQETELV,

(SEQ ID NO:22)

VVLGVVFGI,

(SEQ ID NO:23)

YLQLVFGIEV,

(SEQ ID NO:24)

and

YMIMVKCWMI.

(SEQ ID NO:25)

2 . A composition of claim 1 , wherein the epitope is joined to an amino acid linker.

3 . A composition of claim 1 , wherein the epitope is admixed or joined to a CTL epitope.

4 . A composition of claim 1 , wherein the epitope is admixed or joined to an HTL epitope.

5 . A composition of claim 4 , wherein the HTL epitope is a pan-DR binding molecule.

6 . A composition of claim 1 , further comprising a liposome, wherein the epitope is on or within the liposome.

7 . A composition of claim 1 , wherein the epitope is joined to a lipid.

8 . A composition of claim 1 , wherein epitope is a heteropolymer.

9 . A composition of claim 1 , wherein the epitope is a homoplymer.

10 . A composition of claim 1 , wherein the epitope is bound to an HLA heavy chain, β2-microglobulin, and strepavidin complex, whereby a tetramer is formed.

11 . A composition of claim 1 , further comprising an antigen presenting cell, wherein the epitope is on or within the antigen presenting cell.

12 . A composition of claim 11 , wherein the epitope is bound to an HLA molecule on the antigen presenting cell, whereby when an A2-restricted cytotoxic lymphocyte (CTL) is present, a receptor of the CTL binds to a complex of the HLA molecule and the epitope.

13 . A composition of claim 1 1 , wherein the antigen presenting cell is a dendritic cell.

14 . A composition comprising one or more peptides, and further comprising at least three epitopes selected from the group consisting of:

VLYGPDAPTV,

(SEQ ID NO:1)

YLSGANLNV,

(SEQ ID NO:2)

ATVGIMIGV,

(SEQ ID NO:3)

LLPENNVLSPV,

(SEQ ID NO:4)

KLCPVQLWV,

(SEQ ID NO:5)

KLBPVQLWV,

(SEQ ID NO:6)

SLPPPGTRV,

(SEQ ID NO:7)

SMPPPGTRV,

(SEQ ID NO:8)

KLFGSLAFV,

(SEQ ID NO:9)

KVFGSLAFV,

(SEQ ID NO:10)

VMAGVGSPYV

(SEQ ID NO:11)

ALCRWGLLL,

(SEQ ID NO:12)

FLWGPRALV,

(SEQ ID NO:13)

HLYQGCQVV,

(SEQ ID NO:14)

ILHNGAYSL,

(SEQ ID NO:15)

IMIGVLVGV,

(SEQ ID NO:16)

KIFGSLAFL,

(SEQ ID NO:17)

KVAELVHFL,

(SEQ ID NO:18)

LLTFWNPPV,

(SEQ ID NO:19)

LVFGIELMEV,

(SEQ ID NO:20)

QLVFGIELMEV,

(SEQ ID NO:21)

RLLQETELV,

(SEQ ID NO:22)

VVLGVVFGI,

(SEQ ID NO:23)

YLQLVFGIEV,

(SEQ ID NO:24)

and

YMIMVKCWMI;

(SEQ ID NO:25)

wherein each of said one or more peptides comprise less than 50 contiguous amino acids that have 100% identity with a native peptide sequence.

15 . A composition of claim 14 , wherein one peptide comprises the at least three epitopes.

16 . A composition of claim 14 , comprising at least four epitopes selected from the group of claim 14 .

17 . A composition of claim 14 , comprising at least five epitopes selected from the group of claim 14 .

18 . A composition of claim 14 , comprising at least six epitopes selected from the group of claim 14 .

19 . A composition of claim 14 , comprising at least seven epitopes selected from the group of claim 14 .

20 . A composition of claim 14 , comprising at least eight epitopes selected from the group of claim 14 .

21 . A composition of claim 4 , wherein at least one of the one or more peptides is a heteropolymer.

22 . A composition of claim 14 , wherein at least one of the one or more peptides is a homopolymer.

23 . A composition of claim 14 , further comprising an additional epitope.

24 . A composition of claim 23 , wherein the additional epitope is derived from a tumor associated antigen.

25 . A composition of claim 23 , wherein the additional epitope is a PanDR binding molecule.

26 . A vaccine composition comprising:

a unit dose of a peptide that comprises less than 50 contiguous amino acids that have 100% identity with a native peptide sequence of CEA, HER2/neu, MAGE2, MAGE3, or p53, the peptide comprising an epitope selected from the group consisting of:

VLYGPDAPTV,

(SEQ ID NO:1)

YLSGANLNV,

(SEQ ID NO:2)

ATVGIMIGV,

(SEQ ID NO:3)

LLPENNVLSPV,

(SEQ ID NO:4)

KLCPVQLWV,

(SEQ ID NO:5)

KLBPVQLWV,

(SEQ ID NO:6)

SLPPPGTRV,

(SEQ ID NO:7)

SMPPPGTRV,

(SEQ ID NO:8)

KLFGSLAFV,

(SEQ ID NO:9)

KVFGSLAFV,

(SEQ ID NO:10)

VMAGVGSPYV,

(SEQ ID NO:11)

ALCRWGLLL,

(SEQ ID NO:12)

FLWGPRALV,

(SEQ ID NO:13)

HLYQGCQVV,

(SEQ ID NO:14)

ILHNGAYSL,

(SEQ ID NO:15)

IMIGVLVGV,

(SEQ ID NO:16)

KIFGSLAFL,

(SEQ ID NO:17)

KVAELVHFL,

(SEQ ID NO:18)

LLTFWNPPV,

(SEQ ID NO:19)

LVFGIELMEV,

(SEQ ID NO:20)

QLVFGIELMEV,

(SEQ ID NO:21)

RLLQETELV,

(SEQ ID NO:22)

VVLGVVFGI,

(SEQ ID NO:23)

YLQLVFGIEV,

(SEQ ID NO:24)

and

YMIMVKCWMI;

(SEQ ID NO:25)

and;

a pharmaceutical excipient.

27 . A vaccine composition in accordance with claim 26 , wherein the epitope is YLSGANLNV (SEQ ID NO:2).

28 . A vaccine composition in accordance with claim 26 , wherein the epitope is KLBPVQLWV (SEQ ID NO:6).

29 . A vaccine composition in accordance with claim 26 , wherein the epitope is SMPPPGTRV (SEQ ID NO:8).

30 . A vaccine composition in accordance with claim 26 , further comprising an additional epitope.

31 . A vaccine composition of claim 30 , wherein the additional epitope is a PanDR binding molecule.

32 . A vaccine composition of claim 26 , wherein the pharmaceutical excipient comprises an adjuvant.

33 . A vaccine composition of claim 26 , further comprising an antigen presenting cell.

34 . A vaccine composition of claim 33 , wherein the epitope is bound to an HLA molecule on the antigen presenting cell, whereby when an A2 supertype-restricted cytotoxic T lymphocyte (CTL) is present, a receptor of the CTL binds to a complex of the HLA molecule and the epitope.

35 . A vaccine composition of claim 33 , wherein the antigen presenting cell is a dendritic cell.

36 . A vaccine composition of claim 26 , further comprising a liposome, wherein the at least one epitope is on or within the liposome.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2014
From: IDM PHARMA, INC.
To: BIOTECH SYNERGY, INC.
Reel/Frame 033453/0170 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2014
From: BIOTECH SYNERGY, INC.
To: OSE PHARMA INTERNATIONAL SA
Reel/Frame 033453/0211 →